Researchers at EHU have developed a functional food formulation targeting stress-induced anxiety, according to a study published this week in Frontiers in Nutrition. The intervention, containing fermented microalgae extracts, demonstrated statistically significant reductions in cortisol levels during clinical trials, per lead investigator Dr. Elena Martínez.
How EHU’s Anxiety-Reducing Food Works: A Mechanism Breakdown
The EHU team engineered a food supplement using Spirulina platensis fermented with Lactobacillus rhamnosus, a probiotic strain known to modulate the gut-brain axis. This process enhances the bioavailability of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits neuronal excitability. “The fermentation step increases GABA concentration by 300% compared to non-fermented spirulina,” explained Dr. Martínez, a neurophysiologist at EHU’s Institute of Biomedical Research.
Phase II trials involving 212 participants showed a 28% decrease in self-reported anxiety scores after eight weeks of daily consumption, with no serious adverse events. The study used a double-blind placebo-controlled design, a standard for establishing clinical efficacy.
In Plain English: The Clinical Takeaway
- Key ingredient: Fermented microalgae with elevated GABA levels
- How it helps: GABA may reduce overactive brain signals linked to anxiety
- Proven effect: 28% reduction in anxiety scores during clinical trials
Regional Healthcare Implications: FDA, EMA, and NHS Perspectives
The EHU formulation aligns with the European Food Safety Authority’s (EFSA) 2025 guidelines on functional foods, which permit health claims for products demonstrating “a beneficial physiological effect.” However, the U.S. Food and Drug Administration (FDA) requires more rigorous evidence for disease prevention claims. “While the study shows promise, we await larger-scale trials before considering GRAS (Generally Recognized as Safe) status,” noted FDA spokesperson Dr. Michael Chen.
In the UK, the National Institute for Health and Care Excellence (NICE) is evaluating the supplement for integration into stress management protocols. “If approved, this could offer a non-pharmacological option for patients with mild to moderate anxiety,” said Dr. Amina Khalid, a NICE guideline developer.
Data Table: EHU Clinical Trial Summary
| Phase | Sample Size | Primary Endpoint | Result |
|---|---|---|---|
| Phase II | 212 participants | Anxiety score reduction | 28% decrease (p=0.003) |
| Phase III | 1,200 participants | Cortisol levels | 19% reduction (p=0.012) |
Funding Transparency and Potential Conflicts
The EHU study received €2.3 million in funding from the European Union’s Horizon 2020 program, with additional support from Spanish biotech firm AlgaNova. Both entities disclosed no financial conflicts of interest. Independent reviewers emphasized the need for long-term safety data, as the trials only lasted 12 weeks.
Contraindications & When to Consult a Doctor
The supplement is not recommended for individuals with severe psychiatric disorders or those taking monoamine oxidase inhibitors (MAOIs). “Patients on antidepressants should consult their physician before use,” cautioned Dr. Luis Fernández, a pharmacologist at the University of Barcelona. Symptoms requiring immediate medical attention include persistent gastrointestinal distress, allergic reactions, or worsening anxiety.
Why This Matters: A Public Health Perspective
Stress-related anxiety affects 26% of adults globally, according to the World Health Organization (WHO). Current treatments often involve psychotherapy or medications with side effects. The EHU formulation offers a potential dietary adjunct, though experts stress it should not replace established care. “This is a promising step, but we need more data on its role in comprehensive treatment plans,” said Dr. Sarah Lin, a WHO mental health advisor.
